Sanofi, Orano team up on radioligands

Sanofi and the nuclear corporation Orano have agreed to coinvest in a new Orano subsidiary that will develop radioligands based on lead-212 α-emitting isotopes. Sanofi will invest about $325 million in the new entity. The new radiopharmaceuticals, designed to be more precise than traditional chemotherapy, will target rare cancers, the firms say.

Authors

Publication Details

Journal
C&EN Global Enterprise
Published
2024-10-28
DOI
https://doi.org/10.1021/cen-10234-buscon15
Primary Topic
Linguistic Studies and Language Acquisition
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Sanofi, Orano team up on radioligands

Rowan Walrath
C&EN Global Enterprise
Linguistic Studies and Language Acquisition
article

Sanofi, Orano team up on radioligands

Rowan Walrath
article en

Abstract

Sanofi and the nuclear corporation Orano have agreed to coinvest in a new Orano subsidiary that will develop radioligands based on lead-212 α-emitting isotopes. Sanofi will invest about $325 million in the new entity. The new radiopharmaceuticals, designed to be more precise than traditional chemotherapy, will target rare cancers, the firms say.

C&EN Global EnterpriseVol. 102(34)
Openalex Percentile: Top 83%
Linguistic Studies and Language Acquisition
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Sanofi, Orano team up on radioligands — Rowan Walrath · C&EN Global Enterprise (2024) | TGRS Research Map | TGRS